Skip to main content

Table 2 Predictors of week 16 endpoint scores for individual arms, after controlling for baseline scores

From: Are we drawing the right conclusions from randomised placebo-controlled trials? A post-hoc analysis of data from a randomised controlled trial

  Placebo Group
n= 46
Active Treatment Group
n= 47
  Flushes Greene Climacteric
Scale
HDI-17 Flushes Greene
Climacteric
Scale
HDI-17
  β (SE) p- value β (SE) p- value β (SE) p- value β (SE) p- value β (SE) p- value β (SE) p- value
Age at trial start 0.03 (0.28) 0.93 -0.26 (0.24) 0.28 -0.39 (0.17) 0.03 0.38 (0.32) 0.25 -0.21 (0.25) 0.41 0.23 (0.19) 0.24
Previous Herb Med effective -10.9 (0.07) 0.63 -3.07 (1.84) 0.10 -3.14 (1.37) 0.03 -1.80 (3.04) 0.56 -4.46 (2.40) 0.07 -2.27 (1.88) 0.23
Attitude to menopause -0.63 (2.18) 0.77 0.66 (1.88) 0.73 -0.24 (1.45) 0.87 -3.30 (2.97) 0.27 -4.54 (2.09) 0.04 -3.16 (1.60) 0.055
GCS score, study entry -0.53 (0.17) 0.003 -0.43 (0.16) 0.012 -0.38 (0.13) 0.007 0.23 (0.26) 0.37 0.38 (0.26) 0.15 0.36 (0.18) 0.03
GCS anxiety, study entry -0.97 (0.44) 0.03 -0.82 (0.39) 0.04 -0.33 (0.32) <.001 1.16 (0.47) 0.016 0.65 (0.44) 0.14 0.68 (0.31) 0.02
Change in GCS scores during run-in -0.02 (0.04) 0.59 -0.15 (0.06) 0.013 -0.07 (0.02) 0.005 -0.04 (0.08) 0.68 0.13 (0.08) 0.13 -0.07 (0.05) 0.15
  1. Unstandardised β-coefficient (SE)
  2. Results obtained from hierarchical linear regression analyses